Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Not available.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3324/haematol.2025.287932 | DOI Listing |
Publication Analysis
Top Keywords
lower-intensity chemo-immunotherapy
4
chemo-immunotherapy cladribine
4
cladribine low-dose
4
low-dose cytarabine
4
cytarabine venetoclax
4
venetoclax blinatumomab
4
blinatumomab produces
4
produces high
4
high response
4
response rates
4
Similar Publications
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with -negative B-cell / myeloid mixed phenotype acute leukemia.
Haematologica
June 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston - TX.
Not available.
View Article and Find Full Text PDFLong-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Cancer
June 2021
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Background: The outcome of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. The combination of inotuzumab with low-intensity mini-hyper-CVD (mini-hyper-CVD; cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m × 4 doses) chemotherapy has shown encouraging results.
View Article and Find Full Text PDF